Cohen PA, et al. - Given that, patients with tubo-ovarian high-grade serous carcinoma (HGSC) are stratified by chemotherapy response score (CRS) into complete/near-complete (CRS3), partial (CRS2), and no/minimal (CRS1) response following neoadjuvant chemotherapy (NACT), researchers performed this systematic review and meta-analysis to analyze the contemporary evidence to investigate the prognostic value of CRS in women with tubo-ovarian HGSC treated with NACT. They pooled patient data from 16 sites in 11 countries. Findings revealed a significant link of CRS3 vs CRS1/2 with improved progression free and overall survival. In a real-world setting, CRS gained validation as a robust and reproducible biomarker that can potentially guide therapeutic decision-making.